Compare Tidewater Inc (TDW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tidewater Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Tidewater Inc trades at $84.93 (market cap $4.21B), while Vertex Pharmaceuticals Incorporated trades at $511.21 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 30.3× Tidewater Inc's market cap, and Tidewater Inc is more actively traded (590,005 versus 1,487,944). Which is the better fit depends on your goals — on Pluang, investors hold Tidewater Inc for 26 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TDW | VRTX | |
|---|---|---|
Market Cap | $4.21B | $127.55B |
Volume | 590,005 | 1,487,944 |
Sector | Energy | Health |
52-Week High | $100.61 | $557.96 |
52-Week Low | $47.29 | $407.37 |
Typical Hold Time | 26 Days | 120 Days |
Enterprise Value | $4.25B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tidewater (TDW) trades at $85.19, up 2.15% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong 2025 results with $1.35B revenue and $334.66M net income, though 2026 earnings have missed expectations in two quarters. Recent news includes the completion of the Wilson Sons Ultratug acquisition in August 2026, and institutional interest remains strong with BlackRock's $503.2M investment.
Outlook is cautiously optimistic with a consensus price target of $105.50, but risks include earnings volatility and competitive pressures. The stock offers potential upside from operational improvements and acquisition synergies, yet investors should monitor execution on future earnings and market conditions in the energy sector.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
